title: Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis.
abstract: The limited antifibrotic effect of therapeutic angiotensin blockade, the fact that angiotensin blockade dramatically elevates renin levels, and recent evidence that renin has an angiotensin-independent, receptor-mediated profibrotic action led us to hypothesize that combining renin receptor inhibition and ANG II blockade would increase the antifibrotic effect of angiotensin blockade alone. Using cultured nephritic glomeruli from rats with anti-Thy-1-induced glomerulonephritis, the maximally effective dose of enalaprilate was determined to be 10(-4) M, which reduced mRNAs for transforming growth factor (TGF)-β1, fibronectin (FN), and plasminogen activator inhibitor-1 (PAI-1) by 49, 65, and 56% and production of TGF-β1 and FN proteins by 60 and 49%, respectively. Disease alone caused 6.8-fold increases in ANG II levels that were reduced 64% with enalaprilate. In contrast, two- and threefold disease-induced increases in renin mRNA and activity were further increased 2- and 3.7-fold with 10(-4) M enalaprilate treatment. Depressing the renin receptor by 80% with small interfering (si) RNA alone reduced fibrotic markers in a manner remarkably similar to enalaprilate alone but had no effect on glomerular renin expression. Enalaprilate and siRNA combination therapy further reduced disease markers. Notably, elevated TGF-β1 and FN production was reduced by 73 and 81%, respectively. These results support the notion of a receptor-mediated profibrotic action of renin, suggest that the limited effectiveness of ANG II blockade may be due, at least in part, to the elevated renin they induce, and support our hypothesis that adding renin receptor inhibitor to ANG II blockade in patients may have therapeutic potential.
authors.affiliation: Fibrosis Research Laboratory, Division of Nephrology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
authors.forename: Jiandong
authors.initials: J
authors.lastname: Zhang
authors.forename: Chunyan
authors.initials: C
authors.lastname: Gu
authors.forename: Nancy A
authors.initials: NA
authors.lastname: Noble
authors.forename: Wayne A
authors.initials: WA
authors.lastname: Border
authors.forename: Yufeng
authors.initials: Y
authors.lastname: Huang
mesh_terms: D000804:Angiotensin II / Q000037:antagonists & inhibitors* / Q000097:blood; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D002478:Cells, Cultured; D004359:Drug Therapy, Combination; D015773:Enalaprilat / Q000627:therapeutic use*; D005353:Fibronectins / Q000096:biosynthesis; D005355:Fibrosis; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000473:pathology; D007518:Isoantibodies / Q000276:immunology; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000096:biosynthesis; D034741:RNA, Small Interfering / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors* / Q000235:genetics; D053773:Transforming Growth Factor beta1 / Q000096:biosynthesis; D000093342:Prorenin Receptor
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D005353:Fibronectins; D007518:Isoantibodies; D017395:Plasminogen Activator Inhibitor 1; D034741:RNA, Small Interfering; D011956:Receptors, Cell Surface; D053773:Transforming Growth Factor beta1; C035678:anti-Thy antibody; D000804:Angiotensin II; D015773:Enalaprilat; D000093342:Prorenin Receptor